Combination treatment with paclitaxel and doxorubicin inhibits growth of human esophageal squamous cancer cells by inactivation of Akt

Oncology Reports

Volumn 31, Issue 1, 2014, Pages 183-188

  Lee, Hwan Hee ^a   Ye, Shuai ^a   Li, Xiu Juan ^a   Lee, Kwang Bok ^a   Park, Man Hee ^b   Kim, Soo Mi ^a  

^a Chonbuk National University Medical School   (South Korea)

^b Catholic University of Pusan   (South Korea)

Author keywords

Akt; Apoptosis; Cell cycle; Doxorubicin; Esophageal cancer; Paclitaxel

Indexed keywords

CASPASE 7; CASPASE 9; CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE 1; DOXORUBICIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PACLITAXEL; PROTEIN KINASE B; PROTEIN P53; UNCLASSIFIED DRUG; WEE1 PROTEIN;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL CYCLE G2 PHASE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG POTENTIATION; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CASPASE 7; CASPASE 9; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN B; DOXORUBICIN; ESOPHAGEAL NEOPLASMS; HUMANS; M PHASE CELL CYCLE CHECKPOINTS; PACLITAXEL; PHOSPHORYLATION; POLY(ADP-RIBOSE) POLYMERASES; PROTO-ONCOGENE PROTEINS C-AKT; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84891920780     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2851     Document Type: Article

References (28)

1. Jimenez P, Pathak A and Phan AT: The role of taxanes in the management of gastroesophageal cancer. J Gastrointest Oncol 2: 240-249, 2011.
2. Ajani JA, Barthel JS, Bekaii-Saab T, et al: Esophageal cancer. J Natl Compr Canc Netw 6: 818-849, 2008.
3. Wolf MC, Stahl M, Krause BJ, et al: Curative treatment of oesophageal carcinoma: current options and future developments. Radiat Oncol 6: 55, 2011.
4. Jemal A, Center MM, DeSantis C and Ward EM: Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 19: 1893-1907, 2010.
5. Wright JC: Update in cancer chemotherapy: gastrointestinal cancer, cancer of the small intestines, gallbladder, liver, and esophagus. J Natl Med Assoc 78: 753-766, 1986.
6. Kim SJ, Chung MJ, Kim JS, et al: Deciphering the role of paclitaxel in the SKGT4 human esophageal adenocarcinoma cell line. Int J Oncol 39: 1587-1591, 2011.
7. Legha SS, Ring S, Papadopoulos N, Raber M and Benjamin RS: A phase II trial of taxol in metastatic melanoma. Cancer 65: 2478-2481, 1990.
8. Holmes FA, Walters RS, Theriault RL, et al: Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83: 1797-1805, 1991.
9. Einzig AI, Wiernik PH, Sasloff J, Runowicz CD and Goldberg GL: Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma. J Clin Oncol 10: 1748-1753, 1992.
10. van Steenbergen LN, Elferink MA, Krijnen P, et al: Improved survival of colon cancer due to improved treatment and detection: a nationwide population-based study in The Netherlands 1989-2006. Annal Oncol 21: 2206-2212, 2010.
11. Ajani J: Therapy of localized esophageal cancer: it is time to reengineer our investigative strategies. Onkologie 31: 360-361, 2008.
12. Faried A, Faried LS, Kimura H, et al: Differential sensitivity of paclitaxel-induced apoptosis in human esophageal squamous cell carcinoma cell lines. Cancer Chemother Pharmacol 57: 301-308, 2006.
13. Tacar O, Sriamornsak P and Dass CR: Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. J Pharm Pharmacol 65: 157-170, 2013.
14. Buchholz TA, Stivers DN, Stec J, et al: Global gene expression changes during neoadjuvant chemotherapy for human breast cancer. Cancer J 8: 461-468, 2002.
15. Enzinger PC and Mayer RJ: Esophageal cancer. New Engl J Med 349: 2241-2252, 2003.
16. Rowinsky EK and Donehower RC: The clinical pharmacology of paclitaxel (Taxol). Semin Oncol 20: 16-25, 1993.
17. Park KW, Kang SH, Park KH, et al: Sirolimus- vs. paclitaxel-eluting stents for the treatment of unprotected left main coronary artery stenosis: complete 2-year follow-up of a two-center registry. Int J Cardiol 151: 89-95, 2011.
18. Toiyama Y, Tanaka K, Konishi N, et al: Administration sequence-dependent antitumor effects of paclitaxel and 5-fluorouracil in the human gastric cancer cell line MKN45. Cancer Chemother Pharmacol 57: 368-375, 2006.
19. Zimmermann M, Arachchige-Don AS, Donaldson MS, Dallapiazza RF, Cowan CE and Horne MC: Elevated cyclin G2 expression intersects with DNA damage checkpoint signaling and is required for a potent G2/M checkpoint arrest response to doxorubicin. J Biol Chem 287: 22838-22853, 2012.
20. Kim AH, Khursigara G, Sun X, Franke TF and Chao MV: Akt phosphorylates and negatively regulates apoptosis signal-regulating kinase 1. Mol Cell Biol 21: 893-901, 2001.
21. Zhang HB, Lu P, Guo QY, Zhang ZH and Meng XY: Baicalein induces apoptosis in esophageal squamous cell carcinoma cells through modulation of the PI3K/Akt pathway. Oncol Lett 5: 722-728, 2013.
22. Lin ML, Lu YC, Chen HY, Lee CC, Chung JG and Chen SS: Suppressing the formation of lipid raft-associated Rac1/PI3K/Akt signaling complexes by curcumin inhibits SDF-1alpha-induced invasion of human esophageal carcinoma cells. Mol Carcinog Nov 28, 2012 (Epub ahead of print). doi: 10.1002/mc.21984.
23. Gen Y, Yasui K, Nishikawa T and Yoshikawa T: SOX2 promotes tumor growth of esophageal squamous cell carcinoma through the AKT/mammalian target of rapamycin complex 1 signaling pathway. Cancer Sci 104: 810-816, 2013.
24. Shigaki H, Baba Y, Watanabe M, et al: PIK3CA mutation is associated with a favorable prognosis among patients with curatively resected esophageal squamous cell carcinoma. Clin Cancer Res 19: 2451-2459, 2013.
25. Ou Y, Ma L, Ma L, et al: Overexpression of cyclin B1 antagonizes chemotherapeutic-induced apoptosis through PTEN/Akt pathway in human esophageal squamous cell carcinoma cells. Cancer Biol Ther 14: 45-55, 2013.
26. Nguyen DM, Chen GA, Reddy R, et al: Potentiation of paclitaxel cytotoxicity in lung and esophageal cancer cells by pharmacologic inhibition of the phosphoinositide 3-kinase/protein kinase B (Akt)-mediated signaling pathway. J Thorac Cardiovasc Surg 127: 365-375, 2004.
27. Chen Y, Sun Y, Chen L, et al: miRNA-200c increases the sensitivity of breast cancer cells to doxorubicin through the suppression of E-cadherin-mediated PTEN/Akt signaling. Mol Med Rep 7: 1579-1584, 2013.
28. Yu YH, Kuo HP, Hsieh HH, et al: Ganoderma tsugae induces S phase arrest and apoptosis in doxorubicin-resistant lung adenocarcinoma H23/0.3 cells via modulation of the PI3K/Akt signaling pathway. Evid Based Complement Alternat Med 2012: 371286, 2012.